close

Fundraisings and IPOs

Date: 2017-07-19

Type of information: Grant

Company: Ose Immunotherapeutics (France)

Investors: Bpifrance (France)

Amount: €9.2 million

Funding type: grant

Planned used:

  • The grant will support the EFFI-CLIN project. OSE Immunotherapeutics will lead the consortium collaborating on this project aiming at developing a new generation of checkpoint inhibitor in cancer immunotherapy.
  • The consortium also includes the European Center for Transplantation and Immunotherapy (CESTI), a public organization based in Nantes (France) and Histalim, a SME based in Montpellier (France).
  • Tumours have the particularity of secreting molecules that allow the recruitment and/or generation of suppressor cells that prevent the immune system from eliminating tumour cells. Among the major players in immune dysfunctions promoting tumour growth, pro-tumour and suppressor myeloid cells have been identified (MDSC or Myeloid-Derived Suppressor Cells / TAM or Tumour-Associated Macrophages). OSE Immunotherapeutics was the first to identify the SIRP-alpha target (Signal Regulatory Protein alpha) as a major checkpoint for myeloid cells. The company has developed a selective SIRP-alpha antagonist antibody that transforms the tumour microenvironment by blocking suppressor cells and activating anti-tumour effector cells. The exploration of SIRP-alpha in key indications will be carried out jointly with CESTI and its various technological platforms. Histalim will develop a tool called Histoprofile, for a help in the decision-making in a perspective of personalized medicine. This tool will use multiplex immunohistochemistry techniques (severaltargets measured at the same time on the same tissue) coupled with image analyses. The objective is to characterize the immune profile and the biomarkers found in a patient.
  • EFFI-CLIN will evaluate the safety and the clinical efficacy of new cancer immunotherapy OSE-172 as a monotherapy and in combination in various indications where myeloid cells represent a poor prognosis factor. The project will include in particular the product manufacturing compliant with pharmaceutical standards, translational studies conducted from tumour tissues to measure the presence of immunological targets including SIRP-alpha, and a clinical program planned until the phase 2.

Others: • On July 19, 2017, Immunotherapeutics announced that the company will receive €9.2 million grant from the “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA). This program is overseen by the General commissariat of investment (CGI) and led by Bpifrance. OSE Immunotherapeutics will lead the consortium collaborating on this project named EFFI-CLIN aiming at developing a new generation of checkpoint inhibitor in cancer immunotherapy.

Therapeutic area: Cancer - Oncology

Is general: Yes